Contents of this document
- Decrease in profit due to lower revenue-88 Millions of yen
- Amortization of new core system and other IT-related costs-201 Millions of yen
- New business development, recruitment-related costs, higher personnel expenses and other expense increases-59 Millions of yen
- Focus on the AI- and semiconductor-related industries
- Proactive growth investment, including M&A
- Acquisition of Fixed Assets
- Expanding investment in human capital
- Expansion of new products and services and development of new markets
- ROE6.1 %Year on year against the same period last year+0.7%
- EPS¥117.29Year on year against the same period last year+19.5%
- PBR0.7 timesYear on year against the same period last year-0.1%
- Share price¥1,251Year on year against the same period last year-87.0%
- Forward PER12 timesYear on year against the same period last year-1.0%
- Dividend Payout Ratio45.2 %
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 48,611 Millions of yen (YoY -1.7%) |
| Operating profit | 2,047 Millions of yen (YoY -14.5%) |
| Ordinary income | 2,550 Millions of yen (YoY -12.2%) |
| Net income | 2,112 Millions of yen (YoY +10.2%) |
| Full-year earnings forecast | Net Sales 51,100 Millions of yen / Operating profit 2,070 Millions of yen / Ordinary income 2,565 Millions of yen / Profit attributable to owners of the parent 1,736 Millions of yen / EPS ¥99.32 |
| Breakdown of Factors Affecting the Change | Item Decrease in profit due to lower revenue / Amount -88 Millions of yen, Item Amortization of new core system and other IT-related costs / Amount -201 Millions of yen, Item New business development, recruitment-related costs, higher personnel expenses and other expense increases / Amount -59 Millions of yen |
| Key KPIs | Indicator name ROE / Value 6.1 % / Year on year against the same period last year 0.7 %, Indicator name EPS / Value ¥117.29 / Year on year against the same period last year ¥19.5, Indicator name PBR / Value 0.7 times / Year on year against the same period last year -0.1 times, Indicator name Share price / Value ¥1,251 / Year on year against the same period last year ¥-87, Indicator name Forward PER / Value 12 times / Year on year against the same period last year -1 times, Indicator name Dividend Payout Ratio / Value 45.2 % / Year on year against the same period last year Not disclosed |
| Medium-term management plan targets | Net Sales 55,830 Millions of yen / Operating profit 2,860 Millions of yen / Payout ratio 50 Maintain at or above % / PBR 1 times or more / Target Share Price ¥2,000 / PER 17.5 times / ROE 8 % or higher |
| Financial targets | ROE Target value 8 % / Actual value 6.1 % / PBR Target value 1 times / Actual value 0.7 times / PER Target value 17.5 times / Actual value 12 times |
| Annual Dividend | Annual ¥54 / Interim ¥27 / End of period ¥27 |
| Payout ratio | Actual results 45.2 % / Fiscal year ending March 2027: plan 55.4 % / Medium-term target 50 % |
| Acquisition of treasury shares | Acquisition amount 30 Hundreds of millions of yen / Number of Shares Not disclosed / Period Not disclosed |
| New initiatives | Focus on the AI- and semiconductor-related industries, Proactive growth investment, including M&A, Acquisition of Fixed Assets, Expanding investment in human capital, Expansion of new products and services and development of new markets |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined because capital investment was postponed in fields other than the strong-performing generative AI- and semiconductor-related businesses. Operating profit declined due to the resulting reduction in profit from lower revenue, as well as higher expenses for new business development, amortization of a new core system and other items, recruitment-related costs and personnel expenses.